Transcode Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 10
- Market Cap
- -
- Introduction
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Newton, MA.
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- TransCode Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT06260774
- Locations
- 🇺🇸
Mary Crowley Cancer Center, Dallas, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects with Advanced Solid Tumors
Early Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- TransCode Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT05908773
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath